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Abstract: 
We describe current research that applies epigenetics to a novel understanding of the immuno-neuropathogenesis of HIV-1 viral 
infection and NeuroAIDS. We propose the hypothesis that HIV-1 alters the structure-function relationship of chromatin, coding 
DNA and non-coding DNA, including RNA transcribed from these regions resulting in pathogenesis in AIDS, drug abuse, and 
NeuroAIDS. We discuss the general implications of molecular epigenetics with special emphasis on drug abuse, bar-codes, 
pyknons, and miRNAs for translational and clinical research. We discuss the application of the recent recursive algorithm of 
biology to this field and propose to synthesize the Genomic and Epigenomic views into a holistic approach of HoloGenomics. 
 
Keywords: epigenetics; hologenomics; coding and noncoding DNA; HIV-1; AIDS; NeuroAIDS; molecular medicine paradigm-
shift; translation-clinic 
 
Background: 
In the era of highly active antiretroviral therapy (HAART) 
many factors, including host genetics, HIV strain variation, 
and comorbidities, including drug abuse and co-infection 
with hepatitis C virus (HCV) contribute to the pathogenesis 
of AIDS and NeuroAIDS [1, 2, 3]. Drug abuse is 
considered by many to be an important cofactor in HIV 
pathogenesis and the issue of laboratory data support for 
the deleterious effects of abused drugs on peripheral and 
brain HIV-1 infection impacts on the approaches to combat 
these diseases. Over several decades, laboratory studies 
showed there are in vitro effects of drug abuse (e.g. 
cocaine, opiates, and amphetamines) on brain and immune 
cell function. However, there have been mixed findings in 
epidemiological studies designed to detect deleterious 
effects of abused drugs in vivo [4]. Some studies, for 
example, have demonstrated exacerbating effects of abused 
drugs on HIV peripheral and brain disease [2, 5, 6]. HIV-1 
strain variation is also important for possible vaccine 
strategies against HIV-1 reservoirs in the peripheral and 
central nervous system (CNS) [7] and so the interactive 
effects of HIV strains, drug abuse, and host genetics [1, 2, 
3, 7] impacts on the methods designed to combat 
AIDS/NeuroAIDS. Key issues that remain to be addressed 
are the effects on non-coding DNA and this could prove to 
be a productive avenue of basic and translational research in 
addition to those approaches that have focused on classical 
coding genes.  
 
Deleterious effects may be transmitted through the chromatin 
within non-coding and coding DNA. Drug abuse and HIV 
infection appear to exert effects derived from and directed by 
promoter, non-coding inter-exon, and across intergenic 
sequences. Early studies showed that chromatin remodeling 
was involved in HIV-1 basal transcription as well as in 
response to TNF-α [8]. The HIV-1 Tat protein is essential for 
the initiation of HIV transcription from the integrated HIV 
genome (provirus) through exploitation of host proteins and 
recent evidence also points to pathways that lead to chromatin 
remodeling as a component of HIV transcription. Putative 
pathways studied include bromodomain-binding chromatin 
modifying complexes such as p300/CBP, p/CAF, cdk9/cyclin 
T, and SWI/SNF complexes that via chromatin/nucleosomes 
affect the proximal promoter and ORF regions of the HIV-1 
genome [9].  
 
Susceptibility to HIV Associated Dementia (HAD) is governed 
by many immune-related genes including chemokines as 
discussed in [10] (and below), and the mechanisms involved 
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may include mutated non-coding DNA sequences (e.g. 
chemokine and TNF-α untranslated regions UTRs)). We 
also discuss the Principle of Recursive Genome Function 
[11] in that it subsumes most of the epigenetic mechanisms 
discussed here. 
 
Data sources for epigenetics 
Since the beginning of the AIDS epidemic, many 
approaches have been utilized in HIV research. Although 
epigenetics is not a new field it has been relatively 
neglected in AIDS research. However, it is becoming 
increasingly prominent. Searches of the NIH CRISP 
indicate that in 2008, there are 300 NIH funded grants that 
focus on epigenetics, of which 10 are on epigenetics and 
HIV, 10 on epigenetics and AIDS, and 37 on epigenetics 
and the brain. Web-sites used in our studies included: NIH 
CRISP: http://crisp.cit.nih.gov/; OMIM:  
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=OMIM; 
OMIM Morbid map: 
http://www.ncbi.nlm.nih.gov/Omim/getmorbid.cgi. 
 
NeuroAIDS description 
The AIDS epidemic provides neuropathologists, 
neurologists, and neuroscientists with a multitude of 
neurological complications that require study and suggests 
the importance of epigenetics and the “beyond genome 
approach” in this field. In the opinion of many, the most 
interesting of these complications was and remains HAD. 
Even prior to the advent of HAART in 1996, HAD was 
problematic for neuropathologists. HIV-positive 
multinucleated giant cells were considered the hallmark of 
HIV encephalitis (HIVE) and HIVE was generally thought 
to be the neuropathologic substrate of HAD. However, 
prior to HAART, in some studies, only 50% of patients 
with HAD had HIVE at autopsy; furthermore, there was 
little correlation between the neurocognitive status of the 
patient and the amount of virus in the brain as determined 
by immunohistochemical detection of gp41 [12]. 
Conversely, there was a highly significant correlation 
between the number of activated macrophages and 
microglia in the brain and the severity of neurocognitive 
impairment. 
 
NeuroAIDS and HAART 
In the HAART era, it has been considered that HAD and 
the milder but still disabling syndrome of minor cognitive-
motor disorder (MCMD) remain a significant problem, in 
part because of the increased longevity of those who suffer 
from these diseases [13]. However, the previously weak 
correlation between the amount of virus in the CNS and the 
presence of cognitive impairment has become even more 
tenuous. The reason for this apparent disconnect is 
uncertain. Some patients, whose neurocognitive 
dysfunction is progressive at death, still have no detectable 
virus in CSF or brain [14, 15, 16]. Moreover, it is likely 
that the CNS acts as a reservoir for low (undetectable) 
levels of virus since many of the drugs used in HAART 
poorly penetrate the blood-brain barrier with incomplete 
recovery [17, 18]. Furthermore, although some studies [18] 
emphasize the beneficial effects of HAART, the experience of 
other investigators is that for many HIV-1 infected individuals, 
exposure to HAART has modified but not eradicated the 
deleterious effects of HIV-1 on neurocognitive functioning 
[16]. How can very low or nonexistent levels of virus cause 
progressive damage found in some patients? Alternative 
explanations exist and one possibility is that the virus triggers 
cascades of neurotoxic and inflammatory events that are 
perpetuated even when virus may have been cleared. We 
propose the hypothesis that epigenetic mechanisms are 
involved in these processes.  
 
NeuroAIDS and the new paradigm shift in Molecular 
Biology 
Setting the stage for the important role of the interplay of 
epigenetics and genomics in the pathogenesis of 
neuropsychiatric diseases, including NeuroAIDS, requires a 
quantum paradigm shift in our basic understanding of 
molecular biology. This has been accomplished as described in 
detail by Pellionisz [11] who proposed a new information flow 
recursion process paradigm in all living systems. This theory is 
termed the Principle of Recursive Genome Function and its 
promulgation supercedes two dogmas or axioms concerning the 
genome that were central to biology and molecular medicine 
for the last 38 years. These axioms were fundamental flaws in 
the molecular approach to Translational Medicine and were 1. 
Ohno’s promulgation of the concept that the 99% of the 
genome that is non-coding is garbage or junk DNA and 2. 
Crick and Watson’s contention that there is no flow of 
information from proteins to RNA and DNA [19, 20, 21]. The 
work of McClintock (transposons), Baltimore and Temin 
(reverse transcriptase), and Prusiner (prions), became counter-
examples and demonstrated the limiting nature of these two 
hypotheses.  
 
From the viewpoint of the Principle of Recursive Genome 
Function, we now discuss one of these findings, the 
groundbreaking work done in the 1940’s by Barbara 
McClintock [22]. This work led to the concept of mobile 
elements in the genome that can influence subsequent gene 
expression. This work was inconsistent with the axioms and 
hypotheses generated by Ohno, Crick, and Watson and actually 
predate their work and hypotheses by a decade. In fact, 
McClintock’s work remained at odds with the molecular 
biology establishment for some forty years and was finally 
recognized with McClintock’s Nobel Prize in 1983 [23]. 
McClintock’s insight was her appreciation of the ability of the 
genome to respond to various insults including X-rays and 
insect parasitism mediated by transposable elements that were 
components of the non-coding part of the genome, including 
reiterated sequences. McClintock points out in her 1983 Nobel 
lecture [23], the importance of effects exerted by non-coding 
portions of the genome on the coding portions of the genome. 
Furthermore, she remarks on her findings that some prior 
genome-level event takes several generations to result in full 
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phenotypic expression. Her pioneering work was a 
cardinal, yet for many years largely ignored precursor of 
the Pellionisz principle and further supports the plasticity 
and utility of genome function of both coding and non-
coding portions of the genome in their interplay with the 
environment. 
 
Another important central case supporting the importance 
of a holistic approach inclusive of non-coding DNA and 
epigenetics is mRNA interference (miRNA), an 
evolutionarily conserved process by which eukaryotic cells 
regulate coding DNA expression from their non-coding 
DNA utilizing small, double-stranded RNAs to degrade 
target mRNAs in a sequence-specific manner. Moreover, 
antisense transcripts are involved in the regulation of 
miRNA and result in both activation and inhibition of 
mRNA transcription [24]. Transcriptional and post-
transcriptional gene silencing by miRNAs can thus lead to 
degradation of cellular, as well as viral RNAs, including 
RNA from HIV-1 in the CNS. Additionally, this 
understanding of fundamental mechanisms provides a 
rational basis for double stranded small inhibitory RNAs 
(siRNAs) transfected into specific cells to target particular 
RNAs. Using hairpin motifs, siRNAs are expressed 
intracellularly using molecular therapeutic vectors. This 
potent translational evidence-based epigenetic intervention 
has been envisaged as a technology to counter, for 
example, HIV-1-induced encephalopathy [25]. In addition, 
the miRNA silencing machinery has been shown to have an 
important molecular physiological role in HIV-1 infection 
by regulating viral replication as well. This epigenetic 
process is associated with chromatin assembly, repair, and 
remodeling and it was shown to be dependent upon histone 
acetyl-transferase Tat cofactor [26]. 
 
Molecular signature concepts and variations 
The concept of nucleic acid and amino acid molecular 
signatures has been used in molecular biology to predict 
virus associations with NeuroAIDS as reviewed [27]. This 
approach was extended to information at the DNA level 
and the term recently used is ‘bar-code’. Bar-codes are 
DNA thematic signature sequences that are hypothesized to 
represent epigenetic functions related to cell and organ 
specificity, viral evolution, and disease pathogenesis. It 
follows as well that DNA bar-codes may play a central role 
in evolutionary biology and species specificity [28]. A 
recent analysis of human genomes supports this approach 
and identifies many possible such bar-codes in the 
fundamental genomic modulation in the cellular responses 
to viral infections [29]. Additionally, the bar-code approach 
is useful to identify multiple disease markers [30].  
 
Related to and perhaps conceptually overlapping with bar-
codes are ‘pyknons’, short blocks of DNA sequences in 
non-coding segments of the human genome. The term 
‘pyknons’ is derived from the Greek (πυκνοσ) “piknos” 
meaning serried, dense, or frequent [31]. More than 
380,000 non-overlapping regions of the human genome contain 
60-80 nucleotide-length pyknons. The cell processes associated 
with these pyknons are likely to include cell communication, 
transcription, and regulation of transcription, signaling, and 
transport. It was suggested that pyknons subsume 40% of 
miRNAs identified to date. It is therefore inferred that pyknons 
may be involved in gene regulation or silencing as part of the 
normal cell’s control of transcription.  
 
Thus, short segments of non-coding DNAs that include bar-
codes and pyknons and that produce miRNAs play an 
important role - not yet fully elucidated - in fundamental 
molecular processes [32]. In addition, these advances greatly 
improved the understanding, development, and use of siRNA 
technology to mediate mechanisms to silence genes related to 
HIV/NeuroAIDS [24]. 
 
Studies on gene expression also revealed possible epigenetic 
processes at work in NeuroAIDS. Briefly, gene expression was 
analyzed in cultured human neurons treated with cocaine and 
HIV-1 proteins Tat and envelope (Env) [33]. This serves as a 
model for Neuropsychiatric disease including Dementia in 
NeuroAIDS due to HIV-1 infection compounded by drug 
abuse. At a p < 0.0005, of 12,500 genes examined, 35 genes 
were significantly expressed. The functions of these genes 
included control of transcription, immune-communication, and 
signaling. The gene locations were mapped and found not 
stochastically arranged on the human chromosomes. 
Furthermore, the 35 genes were in proximity to genes known to 
be associated with neuropsychiatric diseases. Several 
hypotheses resulted from this work including that the 
expression of the genes identified was perturbed by the abused 
drug, cocaine, and HIV-1 proteins, Tat and Env; that these 
genes were influenced in transcriptionally isolated groups; and 
that transcription overload (coerced expression due to cocaine 
and HIV-1 proteins) may result in damage to the 
chromosome’s organization and control of the chromatin 
transcription machinery (chromatin remodeling). It should be 
noted that an association of HIV and host-related genes was 
found in additional studies [34, 35]. 
 
Drug abuse and NeuroAIDS Epigenetics 
Drug abuse and HIV infection appear to exert effects derived 
from and directed by promoters, non-coding inter-exon 
stretches of DNA, and across intergenic DNA sequences. 
Briefly, experimental evidence and hypotheses support the 
concept that deleterious effects may be transmitted through 
chromatin as well as non-coding and coding DNA. Moreover, 
it should be noted further that susceptibility to HAD is 
governed by several immune-related genes including 
chemokine genes and that these effects may also be propelled 
by intergenic or non-coding sequences including their promoter 
regions [1, 2, 10, 11, 35, 36]. These are examples of the 
involvement of non-coding DNA sequences (including 
chemokine and TNF-α UTRs) involved in NeuroAIDS. 
Epigenetics and risk for HIV-associated neurocognitive 
disorders (HAND) has been further reviewed by Levine and 
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colleagues [36] with a focus on genetic polymorphisms 
including single nucleotide polymorphisms (SNPs) and 
variable number tandem repeats (VNTRs). Reviewed were 
polymorphisms in a variety of cytokines and their receptors 
(e.g., SDF, MCP-1, MIP-1α, MIP-1β, IL-2, CCR5, and 
TNF-γ) that have been shown to be associated with 
increased risk for HAND and/or progression to AIDS. In 
addition, recent findings indicate that polymorphisms in 
dopamine-related genes (e.g. DAT-1 and DARPP-32) may 
be associated with increased risk of HAND (A. J. Levine, 
personal communication, 2008). We also hypothesize that 
additional related genes with non-coding DNA mutations 
that are implicated in possible association with HAD and 
HAND include dopaminergic function, metabolism, and 
growth factors (e.g. DRD2, DRD4, COMT, DBH, BDNF, 
and ApoE). It is an expected result that all of these genes 
have polymorphisms in their non-coding portions and thus 
are in the epigenetic category that could relate to the risk 
and pathogenesis of HAD and HAND. This is because the 
occurrence of SNPs in the human genome is approximately 
8-9 per 10 Kb of genome [37, 38, 39]. Above and beyond 
the prior discussion of the shortcomings of the Ohno, 
Crick, and Watson hypotheses in molecular biology, it is of 
great interest to note that the rate of SNPs in the genome is 
increased in miRNA domains compared to the ambient 
genome [38].  
 
Thus, the evolution and function of different parts of the 
genome has clearly occurred at differing rates, including 
parts of the non-coding portions as, clearly unanticipated in 
the two prior hypotheses in molecular biology. Current 
work on genetic and biochemical pathways demonstrates 
the importance of non-coding DNA and epigenetics and 
epigenetics-based drugs for translational success in the 
clinic.  
 
Conclusion: 
In conclusion, AIDS and NeuroAIDS are extremely 
complex diseases that, once initiated by HIV-1 infection, 
may be propelled by events that take place at the level of 
intergenic and non-coding DNA, and transmitted through 
the chromatin as well as at the classic level of genes and 
signaling. We propose that research on the epigenetic 
effects on intergenic DNA and chromatin be expanded 
greatly. Moreover, the new Principle of Recursive Genome 
Function provides a more holistic approach for the 
application and translation of molecular biology into the 
clinic. After all, the defeat of disease requires addressing 
the entirety of the human genome and epigenetic factors 
that interact with each other as well as with the 
environment. Thus, the discussion presented here makes a 
compelling case for emerging HoloGenomics and its 
impact on host and viral interactions that determine the 
natural history, effect of treatment, and prognosis of AIDS 
and NeuroAIDS.  
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